Key Events This Week
16 Feb: Lower circuit hit amid heavy selling pressure (₹7.08)
18 Feb: Upper circuit surge with strong buying (₹7.34)
19 Feb: Continued upper circuit rally (₹7.70)
20 Feb: Fourth consecutive upper circuit close (₹8.08)
16 February 2026: Sharp Decline and Lower Circuit Hit
Vivimed Labs opened the week under significant pressure, falling 4.71% to close at ₹7.08, triggering the lower circuit limit. The stock opened at ₹7.59 but quickly declined to ₹7.04 intraday, reflecting panic selling and a lack of buyer interest at these levels. This sharp drop contrasted with the Sensex’s 0.70% gain, highlighting company-specific weakness. The delivery volume also declined sharply, signalling reduced long-term investor participation and increased speculative trading. The stock traded below all key moving averages, underscoring a sustained downtrend and technical weakness.
18 February 2026: Rebound with Upper Circuit Surge
After two days of decline, Vivimed Labs rebounded strongly on 18 February, hitting the upper circuit limit and closing at ₹7.34, a 4.71% gain on the day. This rally occurred despite the Pharmaceuticals & Drugs sector declining 0.12% and the Sensex falling 0.23%, indicating selective buying interest in the stock. The surge was driven by strong demand that exceeded supply, triggering a regulatory freeze on further price appreciation. The stock moved above its 5-day moving average, signalling short-term bullish momentum, although it remained below longer-term averages. Delivery volumes remained subdued, suggesting the rally was led by short-term traders rather than institutional investors.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
19 February 2026: Sustained Buying Pushes Stock to Upper Circuit Again
Vivimed Labs continued its upward momentum on 19 February, hitting the upper circuit limit once more and closing at ₹7.70, a 4.90% gain. The stock outperformed its sector by 2.71% and the Sensex by 2.17%, reflecting strong relative strength. The rally marked the third consecutive day of gains, delivering a cumulative return of 7.53% over this period. Despite the price surge, delivery volumes declined by 17.53%, indicating some profit booking or cautious investor participation. Technically, the stock remained above its 5-day moving average but below longer-term averages, suggesting short-term bullishness amid longer-term resistance.
20 February 2026: Fourth Upper Circuit Close Caps the Week
On the final trading day of the week, Vivimed Labs surged to ₹8.08, marking a 4.94% gain and the fourth consecutive upper circuit close. This strong finish resulted in a cumulative weekly gain of 8.75%, vastly outperforming the Sensex’s 0.39% rise. The stock outpaced its sector by 4.29% and the Sensex by 4.39% on the day, underscoring intense buying interest. The regulatory freeze on price movement again indicated unfilled demand at the upper price limit. Despite this bullish price action, delivery volumes continued to decline, down 29.87% compared to the five-day average, suggesting the rally was predominantly driven by short-term traders. The stock’s position above its 5-day and 20-day moving averages signals short-term strength, though it remains below longer-term averages, indicating that medium-term challenges persist.
Holding Vivimed Labs Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Daily Price Comparison: Vivimed Labs vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-16 | Rs.7.08 | -4.71% | 36,787.89 | +0.70% |
| 2026-02-17 | Rs.7.01 | -0.99% | 36,904.38 | +0.32% |
| 2026-02-18 | Rs.7.34 | +4.71% | 37,062.35 | +0.43% |
| 2026-02-19 | Rs.7.70 | +4.90% | 36,523.88 | -1.45% |
| 2026-02-20 | Rs.8.08 | +4.94% | 36,674.32 | +0.41% |
Key Takeaways
Strong Weekly Outperformance: Vivimed Labs outpaced the Sensex by 8.36% over the week, driven by a remarkable four-day rally following an initial sharp decline.
Volatility and Circuit Hits: The stock experienced both lower and upper circuit hits, reflecting heightened volatility and a significant supply-demand imbalance throughout the week.
Technical Momentum vs Fundamental Caution: While short-term technical indicators show bullish momentum with prices above 5-day and 20-day moving averages, the stock remains below longer-term averages, signalling unresolved medium-term resistance.
Declining Delivery Volumes: The consistent drop in delivery volumes suggests that the rally is largely driven by short-term traders rather than sustained institutional buying, raising questions about the durability of the gains.
Strong Sell Mojo Grade: Despite the price surge, the stock retains a Mojo Score of 24.0 and a Strong Sell rating, reflecting fundamental concerns that investors should weigh carefully.
Conclusion
Vivimed Labs Ltd’s week was characterised by a dramatic reversal from a lower circuit hit to a sustained rally with four consecutive upper circuit closes, culminating in an 8.75% weekly gain. This performance significantly outpaced the Sensex and sector indices, highlighting strong short-term buying interest. However, the persistent decline in delivery volumes and the stock’s position below key longer-term moving averages suggest that this rally may be speculative and not yet supported by fundamental improvements. The Strong Sell Mojo Grade further underscores the need for caution. Investors should monitor upcoming trading sessions closely for confirmation of trend sustainability or signs of reversal, balancing the technical momentum against underlying risks and liquidity constraints.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
